arrow
D

Daisuke Arai

keio university
H指数:22
被引数:2,976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Durvalumab在表皮生长因子受体突变型III期非小细胞肺癌患者接受同步化放疗后的应用:一项日本真实世界数据分析

2025-05-270
OA
Long COVID among the first three waves of COVID-19 in Japan: a multicentre cohort study
2024-12-250
OAAI
Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSIFACT exploratory analysis)
2023-11-010
OA
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

晚期非小细胞肺癌中基于铂类化疗联合程序性死亡-1阻滞后ramucirumab联合多西他赛的多中心真实数据: NEJ051 (反应性研究)

2023-05-0110
PRE
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

单细胞分析和宿主遗传学强调先天免疫细胞在新型冠状病毒肺炎严重程度中的作用

2023-04-2418
OAAI
Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
2023-01-0111
PRE
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer A Real-World Setting
CHEST
IF8.6
2022-11-0122
PRE
Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis

高龄晚期非小细胞肺癌的真实临床实践: 一项回顾性多中心分析

2022-09-015
PRE
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force
2022-08-2213
OAAI
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
2022-07-0113
OA
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)

奥希替尼作为一线治疗晚期表皮生长因子受体突变阳性非小细胞肺癌 (OSI-FACT)

2021-12-0146
PRE
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
2021-06-0320
OA
Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

晚期肺癌患者及其家庭照顾者的诊断关注趋势: 一项为期2年的纵向研究

2021-03-2411
OAAI
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

分子动力学模拟指导的EGFR罕见突变肺癌药物敏感性预测

2019-05-0141
OAAI